The pharmaceutical industry is undergoing a remarkable transformation, with advanced modalities like antibody-drug conjugates (ADCs) and radiopharmaceuticals driving the evolution of precision medicine. These innovations are not only redefining drug development but are also improving patient outcomes through targeted therapies, reduced side effects, and expanded treatment options. The...
On 16 October at the 2024 ISPE Annual Meeting & Expo in Orlando, Florida, USA, Emer Cooke, European Medicines Agency (EMA) Executive Director and chair of the International Coalition of Medicines...
In this blog post, Charlie Wakeham, Director of WakeUp to Quality and Chair of the ISPE GAMP® Global Steering Committee, shares a recap of the ISPE Australasia Digital Innovation Conference, which took place 24 – 25 September 2024.
All economic sectors, including life sciences, are undergoing a significant transformation driven by the increasing focus on integrating environmental, social, and governance (ESG) criteria into their strategies and activities. This shift is crucial as companies face growing pressures from stakeholders such as customers, regulators, suppliers, and employees to act responsibly and...
Designing a monoclonal antibody (mAbs) production facility presents a series of unique challenges, balancing regulatory compliance, efficiency, sustainability and flexibility. Through careful planning and design, companies can create production environments that meet growing demands while optimizing operational efficiency.
